Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat for Exercise Intolerance Post-PEA
NCT03409588Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jun 2018
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat in Chronic Thromboembolic Disease (CTED), sponsored by University of Colorado Denver. Started Jun 2018; status: completed.
02
Drugs
riociguat
03
Conditions
Chronic Thromboembolic Disease (CTED)
Beyond the preview
Go deeper on NCT03409588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409588.